American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • VICKI: A phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC)
    Meeting Abstract

    Lindeman, G. J.; Hamilton, E.; Krop, I.; Lim, B.; Modi, S.; Saura, C.; Desai, R.; Danner, B. J.; Fernando, T. M.; Kong, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): AMEERA-1
    Meeting Abstract

    Linden, H. M.; Campone, M.; Bardia, A.; Ulaner, G. A.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Chandarlapaty, S.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
    Meeting Abstract

    Ma, C. X.; Suman, V.; Leitch, A. M.; Sanati, S.; Vij, K.; Unzeitig, G. W.; Hoog, J.; Watson, M.; Hahn, O.; Guenther, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)
    Meeting Abstract

    Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Meeting Abstract

    Jhaveri, K.; Juric, D.; Varga, A.; Turner, N.; Schmid, P.; Saura, C.; Oliveira, M.; Krop, I. E.; Kalinsky, K.; Italiano, A.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Latest findings from the breast cancer cohort in SUMMIT - A phase 2 'basket' trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer
    Meeting Abstract

    Jhaveri, K.; Saura, C.; Guerrero-Zotano, A.; Spanggaard, I.; Bidard, F. C.; Goldman, J. W.; Garcia-Sáenz, J. A.; Cervantes, A.; Boni, V.; Crown, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Development of a breast cancer risk assessment model for ATM mutation carriers incorporating tyrer-cuzick and a polygenic risk score (PRS)
    Meeting Abstract

    Gallagher, S.; Hughes, E.; Rosenthal, E.; Kurian, A. W.; Domchek, S.; Garber, J.; Probst, B.; Morris, B.; Tshiaba, P.; Roa, B.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Clinical-grade detection of breast cancer in biopsies and excisions using machine learning
    Meeting Abstract

    Hanna, M. G.; Raciti, P.; Godrich, R.; Casson, A.; Viret, J.; Lee, D.; Lee, M.; Bozkurt, A.; Sue, J.; Dogdas, B.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Digital MammaPrint and BluePrint using machine learning and whole slide imaging
    Meeting Abstract

    Glas, A. M.; Reis-Filho, J. S.; Wehkamp, D.; Dodgas, B.; Delahaye, L.; Godrich, R.; Mollink, J.; Casson, A.; Witteveen, A.; Viret, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: